All participants were adults with obesity and moderate to severe sleep apnea. In the first study, Zepbound resulted in an average reduction of 27.4 AHI events per hour among participants who did ...

The FDA approved tirzepatide (Zepbound) for adults with moderate-to-severe obstructive sleep apnea (OSA ... mean change at ...

ILI was associated with an improvement of obstructive sleep apnea, determined by a mean AHI decrease of 9.7 events per hour compared with that in the DSE patient group. Study participants with a ...

“We know that disordered breathing and disturbed sleep ... apnea-hypopnea index (AHI), which counts pauses in breathing per hour and associated drops in oxygen levels. The normal level in adults ...

INDIANAPOLIS (dpa-AFX) - The U.S. Food and Drug Administration approved Zepbound (tirzepatide) for the treatment of moderate to severe obstructive sleep apnea or OSA in adults with obesity ...

Use of positive airway pressure therapy decreased the risk for all-cause and cardiovascular mortality in adults with obstructive sleep apnea ... the Newcastle-Ottawa Scale was used in NRCSs.

IHL-42X is designed to treat OSA by targeting its underlying pathophysiology. An oral fixed-dose combination of dronabinol and acetazolamide, IHL-42X is currently advancing through the RePOSA Phase ...